South African Miner Claims - Anglo American a Target

This on-line  article from South Africa provides an update on the efforts of  Leigh Day & Co. and the Legal Resources Center of South Africa as to  litigation on behalf of South African miners. Current claims include claims for gold miners, with the claims against Anglo-American dating back to 2004, as described here by Leigh Day. 

Prior claims for miners were prosecuted against Cape Industries because of its appalling treatment of asbestos miners. Click here to see one of several on-line editions of pictures "from  the collection of pathologist Dr J C Wagner showing a woman at a Cape Blue mine in Swaziland, southern Africa. She is sealing numbered bags of blue asbestos rocks (crocidolite) for export. Wagner's research, and that of his colleagues, led to the identification of the causal link between exposure to blue asbestos and the lung cancer mesothelioma."

Richard Meeran has been an active force in both cases, as described here.

Private Litigation Funders Keep Growing - Burford More than Doubles to Become the World's Largest

Private litigation funder Burford Capital has just raised another $ 175 million to become the world's largest private investor in litigation. Prior funds were raised through an IPO on AIM, as described here. The new round of funding is described here.  A successful prior Burford investment is described here.

The world of public and private litigation is fascinating. Any bets on how long will it be before we see IPOs for litigation funds raised to target specific companies or specific industries ?  By 2020 seems like a good bet to me, and that may well be longer than it actually takes.

Great Looking Upcoming Conference - 4th International Conference on the Globalization of Collective Litigation, with a Focus on Latin America

There’s an upcoming, great looking conference December 10, 2010 conference on the globalization of collective litigation.  The conference is at FIU in Miami.

The conference scope is broad, and includes sessions focused on Latin America and litigation financing. Details are set out below.  The Latin American focus includes a strong contingent of lawyers. Panel 3 on litigation funding is unusual because of its focus on both public and private litigation funding, and other forms of targeted litigation. That’s a broader form of thinking about litigation funding, and obviously make sense. After all, consider the great results obtained by the ACLU’s beautifully planned and executed attack on gene patents that simply describe the layout of a gene. That success has now been followed by the US Department of Justice  taking the same position, thus reversing years of prior thinking. Specifics on the entire conference are set out below; set out first is a description of  panel 3 on litigation funding: 

 “The general theme is to illuminate different ways of funding mass claims, and identify the big problems and issues, and what is coming up in the future. As funding is a developing topic, we want to capture the trends and discuss different options, from the public financing of litigation to the use of legal aid board schemes, consumer associations and NGOs with reference to specific cases such as Dexia, law firm funding and also capture the general insurance perspective.”

4th International Conference on the Globalization of Collective Litigation

Florida International University College of Law

Miami, Friday, December 10th, 2010

About the conference:

This conference, co-organized by professors Manuel A. Gomez (Florida International University College of Law) and Deborah R. Hensler (Stanford Law School), is the fourth in the series of international conferences on the global spread of collective litigation begun in 2007 at Oxford University. It will bring together academicians, policy analysts and legal practitioners to systematically review the status of collective litigation around the world with special focus on Latin America, a region signaled by a growing interest in protecting collective rights, the passage of legislation that provides for class actions and similar mechanisms, and the increased participation of domestic courts in deciding cases that involve large-scale accidents, environmental harms, exposure to toxic materials, defective products and financial injuries.

The conference will address issues of critical importance including financing, coordination and enforcement. It will also serve as a vehicle to exchange information about how the collective litigation rules work in practice, who is availing themselves of these procedures and for what ends, and what the economic and social consequences are for individuals, business, and the public interest.

The full agenda and registration information is available here. :

The conference will consist of four sessions. The two morning sessions will be devoted to Latin America. The two afternoon sessions will be devoted to funding issues (session 3) and general trans-national issues (session 4). Set out below is a brief description of each panel:

Panel 1: The protection of collective rights in Latin America

The general theme is to highlight how the protection of collective actions has evolved in the region, from the writ of Amparo and other court-devised mechanisms (e.g. estado de cosas inconstitucionales inColombia) to the enactment of special legislation geared to protect collective rights (consumer protection statutes, recent reform of the Ley de Reforma del Tribunal Supremo de Justicia de Venezuela, etc). Panelists will also address briefly the policy orientations in specific jurisdictions and what is coming up in the future.

Panel 2: Obstacles and incentives to collective litigation in Latin America

The general theme is to highlight different incentives and identify the big problems and issues affecting the development of collective actions in the region, and to discuss possible trends in light of the different reform efforts in different jurisdictions.

Panel 3: Funding Issues: Public versus Private Financing

The general theme is to illuminate different ways of funding mass claims, and identify the big problems and issues, and what is coming up in the future. As funding is a developing topic, we want to capture the trends and discuss different options, from the public financing of litigation to the use of legal aid board schemes, consumer associations and NGOs with reference to specific cases such as Dexia, law firm funding and also capture the general insurance perspective.

Panel 4: Trans-jurisdictional litigation, coordination and enforcement issues

This panel will focus on:

(1) What happens when class actions and other forms of group litigation procedures are thrown into the mix;

(2) How the growth of trans-national networks of private lawyers is affecting forum selection; and

(3) How the growth of trans-national litigation and especially collective litigation is affecting international commercial/investor arbitration practices and other forms of private "ADR."

 

 

.  

Science and Engineering Powerhouse University of Illinois Takes on Long Term Partnership with Science Olympiad for Youths

Much of our future lies in science. Accordingly, as a fan of the University of Illinois (see below) and science,  it was great to see the following news regarding the U of I taking on another  role in pushing science forward. How ?  By entering into a long-term partnership with the Science Olympiad. What is the that? It's a national program that encourages and provides real opportunities and scholarships for kids interested in science. The news is set out below, and is posted here

 

 Chicago-Based Science Education Non-Profit is Largest Team Science Competition in the United States; University of Illinois Ranked Top Ten in Science and Engineering 

 

 

CHICAGO, November 18, 2010 -- University of Illinois at Urbana-Champaign (UIUC), one of 

the leading science and engineering institutions in the United States and nationally-recognized 

Science Olympiad have announced a long-term partnership. Science Olympiad is a 27-year-old 

national science competition that focuses on student teams working together on science, 

technology, engineering and math (STEM) challenges. Aligned to the National Science Education 

Standards developed by the National Research Council, Science Olympiad’s broad scope of 

events touch every letter in STEM. 

 

"We are honored to partner with the University of Illinois," said Dr. Gerard Putz, Science 

Olympiad co-founder and president.  "Its commitment to the on-campus I-STEM Education 

Initiative mirrors Science Olympiad's mission to connect K-12 STEM learning, higher education 

and workforce development.  This partnership secures a rock-solid foundation for Science 

Olympiad moving forward." 

 

The merger will employ a three-year transition period during which I-STEM and UIUC will work 

closely with Science Olympiad to increase staffing and programs. After the 2013 National 

Tournament, Science Olympiad’s national operations will be housed on the UIUC campus, and in 

2014, the University of Illinois plans to host the 30th Anniversary of the Science Olympiad 

National Tournament. In 2010, UIUC offered 62 gold medal winners in the high school division 

of the Science Olympiad National Tournament a four-year, full-ride tuition waiver, valued at 

more than $100,000 each. 

 

A key highlight of the merger is the formation of the Science Olympiad Endowment at the 

University of Illinois Foundation, which will be devoted to serving the philanthropic, service- 

oriented goals of Science Olympiad. Major priorities include: 

 

Awarding grants to communities for Urban and Rural Schools Initiatives 

Awarding grants and professional development to state Science Olympiad organizations 

Providing scholarships or fellowships to Science Olympiad Alumni Association members 

Click here to go the ScienceOlympiad website; a basic summary is set out below.

WHAT IS SCIENCE OLYMPIAD

Science Olympiad is an international non-profit organization devoted to improving the quality of science education, increasing student interest in science and providing recognition for outstanding achievement in science education by both students and teachers. These goals are accomplished through classroom activities, research, training workshops and the encouragement of intramural, district, regional, state and national tournaments. Science Olympiad tournaments are rigorous academic interscholastic competitions that consist of a series of team events, which students prepare for during the year. These challenging and motivational events are well balanced between the various science disciplines of biology, earth science, chemistry, physics and technology. There is also a balance between events requiring knowledge of science concepts, process skills and science applications. In addition, during the day there are open house activities that consist of science and mathematics demonstrations, activities and career counseling sessions conducted by professors and scientists at the host institution occurring concurrently with the events.

Many states and regions have organized physics, biology or chemistry competitions, but few have combined all disciplines in one large Science Olympiad. The excitement of many students from all science areas competing and cheering one another on to greater learning caused one school district to coin the phrase "intellete". When they searched for a place to house their newly won Science Olympiad State Championship trophy, the only location available was outside the principal's office in the "athlete" showcase, so they convinced the school board to build an "intellete" showcase. One of the goals of the Science Olympiad is to elevate science education and learning to a level of enthusiasm and support that is normally reserved only for varsity sports programs.

 

Please forgive today's boosterism for the University of Illinois and science. The roots for it lie in my University of Illinois heritage and great pride in the school. I grew up in Champaign-Urbana,  hometown of  the U of I's main campus, and lived on campus while obtaining my undergrad degree in business in 1980. ( My high school science teacher managed to make science boring for me, hence the business degree.)  The roots also run deeper. Dad was engineering professor at the U of I, and Mom was a senior administrative assistant to various senior administrators. My sister is a molecular biologist who earned her bio degree from the U of I and then moved west to work with the great researchers at Salk Labs. My brother is a U of I trained engineer/businessperson with a major international manufacturing business. 

Tags:

Lloyds Report on Cell Phone Cancer Risks

Lloyds issued this November 10, 2010  report on cell phone risks. The summary is obviously written to support an insurance industry view of the facts. That said, it's helpful as a summary of research, and perhaps useful as a roadmap to insurer thinking on the subject.  

Tags:

Selling Risky Products - Is a Clear Conscience Enough - Global Approaches Needed

Suppose a new a business is planning to undertake global sales of  products that contain known or suspected carcinogens. Suppose also that the proposed seller declares that he has a clear conscience on the rationale that the products are desired by buyers, and that short-term measures may or will block  exposures during production, and during initial sale and use of the product. Suppose  also that the proposed products inevitably will cause exposures down the line ?  

Should that new business be allowed to go forward ? Should the business and its products be regulated by global corporate and tort law that does not yet exist ? Should the business and its products  be regulated solely by the law of the place of incorporation ?  The law of the place where people become sick? Should there be special rules that require the business to in essence buy and escrow real, collectible long-term insurance commensurate with the risks ? Or, should the business simply proceed ahead  with the freedom to disappear out of existence before long-term harms become apparent.   

To give context to the questions, consider a couple of examples from asbestos mining. For one, consider this article on an African mine that is a financial disaster. Consider this prior post with information from an article focused on a Russian-sponsored asbestos mine and industry in the town of Asbest.  And  consider also this latest Canadian article regarding the ongoing debate about whether there will or should be new investment in a Canadian asbestos mine. On one hand, scientists, doctors and some ngo advocates argue that  asbestos should be banned globally. But some mine workers, government officials, and capitalists argue that sales should continue because the fibers help to create building products for use in nations such as India. The proposed new business owner declares that he has a "clear conscience."  According to this Financial Times article on the mine:  "Expansion would boost production from the 100-year-old mine from an estimated 15,000 tonnes this year to 180,000 tonnes in 2012 and an eventual capacity of 260,000 tonnes, or about 10 per cent of global production."

Also consider tobacco. On the human  scale, the annual  global toll of cancer deaths by smoking is  predicted to soon each eight  million deaths.  On the financial scale, the annual global cost of all cancers is estimated at   $ 1.5 - 2.  trillion.   So, over a decade, we know that tobacco sales will cause tens of  millions of agonizing deaths, and some trillions of dollars of money spent on health care for humans poisoned by products sold for a profit. 

Conclusion? Globalization requires new legal rules. Traditional jurisdictional, corporate and choice of law rules are losing usefulness and fairness. Decisions to sell carcinogens on a global scale should be subject to at least minimum global rules. Business will complain that potential new global rules are presently unknown and create uncertainty. That's true. But the business knows that it is selling an actual or suspected carcinogen, and knows that the sales create uncertainty and risks of death for end-users and so-called "bystanders."   What moral claim does  the business have for certainty for itself when it knows it is creating uncertainty for human beings?

Another Reason to be Grateful for Good Health - New England Journal of Medicine Publishes a Major New Study Finding that Medical Malpractice Remains Ongoing at High Rates

Updated with Newly Available Link to NEJM Article

Thanksgiving of course is an excellent day to give thanks in general for good health. Now, here's another reason to be thankful for good health. 

The New England Journal of Medicine published on Thanksgiving a major new study  on medical malpractice. Sadly, the study finds that medical malpractice is continuing at high levels. The study is summarized in this Denise Grady article in the NYT. Ms. Grady's article also includes a link to and brief summary of the major 1999 study that reached the same general conclusions.  Some key excerpts are below.  The full text of the NEJM article is  on-line here, and is free.

Best wishes to all for a joyous and peaceful Thanksgiving.

And, after the holiday, remember to cite the  new study when someone blames lawyers for the "med mal crisis."  Lawyer bashing is easy, but wrong. In general, doctors and hospitals are creating their own problems, some with obvious links to short-staffing.

Dr. Landrigan’s team focused on North Carolina because its hospitals, compared with those in most states, have been more involved in programs to improve patient safety.

But instead of improvements, the researchers found a high rate of problems. About 18 percent of patients were harmed by medical care, some more than once, and 63.1 percent of the injuries were judged to be preventable. Most of the problems were temporary and treatable, but some were serious, and a few — 2.4 percent — caused or contributed to a patient’s death, the study found.

The findings were a disappointment but not a surprise, Dr. Landrigan said. Many of the problems were caused by the hospitals’ failure to use measures that had been proved to avert mistakes and to prevent infections from devices like urinary catheters, ventilators and lines inserted into veins and arteries."

 

Science Leaps Ahead - Now, Some Full 3D Tumors Can Be Grown in a Dish, Leading to Direct Observation of Outcomes and Rapid Testing

Just in time for Thanksgiving, a new scientific first arrives in the form of a breakthrough in cancer research tools. The gist ? Scientists have now figured out a way to transform ordinary human tissue into a  tumor growing in a dish. Result ? A strong possibility that potential cancer-treatment agents can be quickly tested and watched in the dish, with results observable in days instead of the months normally needed for animal studies. 

For people with cancer now,  days matter. That's surely one reason why the research is published  in Nature Medicine, one of the world's leading scientific journals.

Key excerpts are set out below from this summary article in ScienceDaily. The Nature Medicine abstract is here.

 

"Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals."

***

Studies of this type, which used to take months in animal models, can now occur on a time scale of days," said Paul Khavari, MD, PhD, the Carl J. Herzog Professor and chair of dermatology at Stanford. The researchers focused on epithelial cells, which line the surfaces and cavities of the body. Cancers of epithelial cells make up approximately 90 percent of all human cancers.

***

 The researchers took advantage of their new "tumor-in-a-dish" model to test 20 new experimental anti-cancer drugs. Many of these drugs cannot be easily tested in animals because they are difficult to administer and may be toxic in their current form. But Khavari and Ridky were able to quickly home in on three promising candidates that stopped the altered epithelial cells from invading through the membrane. While the drugs will still have to be optimized for testing in animals, this type of pre-screening allows researchers to narrow down the possibilities.

Tags:

Dr. Wolfram Ostertag - Former Students and Others Write in Tribute to an Inspiring Scientist Focused on Blood Stem Cells and Related Virus Research

In view of the current controversy about patents for simply describing a gene, it's especially interesting to read a tribute written by former students of a great scientist with a major interest in the how and why of   hematopoietic stem cells. Hematopoietic stem cells are the stem cells that create all the blood cells needed to live.  

Judging by this tribute in the scholarly journal titled Human Gene Therapy, Dr. Wolfram Ostertag was quite a scientist and inspirational leader who made profound contributions as a scientist and a leader for young scientists.  Another tribute article is here, and notes that he was first published in Science at age 21. That's akin to arguing to the Supreme Court at age 21. 

Dr. Ostertag also declined to obtain a patent for findings now used to help block AIDS. Set out below is a key excerpt from the tribute. As to his work on AZT,  it appears it was but a small part of his life's work. The entire tribute is well worth reading  to gain some insights into how and why great scientists lead.  

"Almost forgotten but highly remarkable is his important role in the discovery of the antiretroviral activity of azidothymidine (AZT) (Ostertag et al., 1974; Dube and Ostertag, 1991). Back in 1974, he found that AZT inhibits the replication of murine leukemia virus, his preferred genetic tool since the early 1970s. From an economic perspective, it may have been his greatest mistake not to have patented this discovery, which occurred many years before HIV emerged as a new plague of human existence. Work started in his department has led to the development of highly efficient genetic principles to block the entry of HIV into cells (Hildinger et al., 2001)."

Tags:

The Ultimate Litigation Funding - Private Equity Buying Law Firms - Now AmLaw Really Sees It Ahead

Everyone is starting to see the obvious. The cover story of the current issue of American Lawyer dramatizes a private equity firm making a  2020 purchase of a major law firm.  The issue also includes this article which notes that outside investment in law firms takes hold next year in the UK. 

The article includes predictions  that American law firms will be the subject of outside investment by non-lawyers within 15-20 years. It may well take that long because some of our states are mired in the past, and are driven by parochial local interests.  If it takes that long, US lawyers will have ceded much to the rest of the world. The move to a fully entrepreneurial model for law has been obvious since Slater & Gordon went public back in 2007, and as contingent fees have taken off around the world.  

When private equity will soon be able to buy law firms, one wonders why the US Chamber of Commerce keeps fussing about  litigation funding. After all, buying law firms is the ultimate form of litigation funding. But, delaying the inevitable no doubt suits the short-term goals of too many.

Bankers and Others Losing the Foreseeability Defense for the CDO Fiasco

Remember when Paul Krugman was exploding with outrage after Goldman' Sach's Mr. Blankfein testified to Congress that the financial meltdown was like a hurricane no one could foresee ? Remember the Epicurean Dealmaker's  admonition that the lack of foresight was self-induced?

Perhaps Mr. Blankfein drank his own Kool-Aid.  But he was in fact dead wrong, according to this Jason Zweig article in  the Wall Street Journal, which includes its own links to other materials.  As the article describes,  the CDO melt-down was foreseen in concept about seven decades ago by a University of Chicago economist named Melchior Palyi. (One can reasonably wonder if the "find" on Mr. Palyi's work is related to litigation.)  In a similar vein, the bloggers at  The Conglomerate were last April writing about a 2002 University of Illinois law review as very prescient. That discussion is here.

Back to the merits. A fundamental problem according to Mr. Palyi?  Lousy ratings of the safety of bonds. Key excerpts from the article are as follows: 

Mr. Palyi, then teaching at the University of Chicago, was a vocal skeptic from the outset. Looking back into the 1920s, he found that investment-grade bonds went bust with alarming frequency, often in the same year they were rated. On average, he showed, a bank that followed the new rules would end up with a third of its bond portfolio going into default.

The record was so unreliable that it would be "still more responsible," Mr. Palyi growled, to "stop the publication of ratings altogether." He was especially troubled that the new banking rules switched the responsibility for credit safety from bankers—and even bank regulators—to ratings firms.

"From there," he warned, it "will have to be shifted again—to someone else," presumably taxpayers. Liquidity, Mr. Palyi argued, was being replaced by what he scornfully called "shiftability," a new kind of risk that could someday "be magnified into catastrophic dimensions."

In response to his criticism, government researchers studying how to apply bond ratings changed their method for calculating the performance of investment-grade bonds. By 1943 they had come up with an oddly contorted median that magically improved the track record of the ratings providers.

This switcheroo, recently documented for the first time by economists David Levy of George Mason University and Sandra Peart of the University of Richmond, legitimized the new regulatory model and flushed Mr. Palyi's criticism down the memory-hole of history. Credit ratings, in the words of economist Lawrence White at New York University, acquired "the force of law."

SEC Official Urges Support for Greater Disclosure of Contingent Litigation Risks

At a financial executives meetng which included  a talk by the acting FASB chief on FAS 5,  an SEC official publicly stated that the SEC expects broader corporate disclosure of litigation risks. The original article is here.  AmLaw's Alison Frankel covers the story here. Her story includes a link to and  praise for  a prior article by Susan Beck in which Ms. Beck took strong issue with the corporations that seek to avoid disclosure of litigation risks.

Update - Big Tobacco Loses Big - Examples of the Variance in Mass Tort Trial Outcomes

Update on November 1 post

Big tobacco's winning streak  came to an abrupt end. As explained below, outcomes vary for tort trials, and repetitive claims tend to "mature" over a period of years and trials. New science, however, also will change the maturation process.  Accordingly, it  is not wise to declare or presume victory is at hand after a few wins.

As described in this Law.com article by David Bario, the end of the defense string arrived with a plaintiff's verdict for  $ 80 million, which includes a punitive damages component at less than the  much-argued 10:1 ratio.   According to the article:

"Before the recent defense hegemony, plaintiffs lawyers at Searcy Denney Scarola Barnhart & Shipley had taken three Engle progeny cases to trial and won them all, including the last plaintiffs verdict before Big Tobacco began winning. Earlier this month, David Sales and James Gustafson went to trial with the firm's fourth Engle case. And on Monday, state court jurors in Bronson, Fla., delivered their client a verdict that breaks the defense winning streak in a big way.

The jury hit R.J. Reynolds with $72 million in punitive damages and $8 million in compensatory damages, finding that the tobacco company was 90 percent responsible for the death of James Horner, who died of lung cancer after smoking for 60 years. Here's
the amended complaint Searcy Denney filed on behalf of Horner's daughter, Diane Webb; and here are the verdict forms the jury returned on compensatory and punitive damages."
 

November 1 Post

In mass tort litigation involving repeated trials of similar issues, the outcomes can go back and forth as the parties shift strategies and tactics. Thus, Law.com reports that the cigarette companies recently have won six straight Engle trials in Florida. Plaintiff's counsel say they will keep trying cases, and estimate that the defendants are spending   $ 5 million per trial.  The defense string no doubt is encouraging for the defendants. 

But, the defense win streak follows an even larger number of wins for plaintiffs at the start of the series of trials, as described here. Defendants also lost their 11th Circuit effort to avoid the series of trials. So, now it's up to plaintiffs to look afresh at their tactics and see if the trial approach needs freshening or improvement.

Perhaps the David Bernick factor is now at work in the Engle trials. In any event, the Engle trials are just one part of part of global tobacco litigation, as described here and here. And then there are media efforts too.

Tags:

Update - Big Tobacco Loses Big - Examples of the Variance in Mass Tort Trial Outcomes: Tobacco Companies Lost Most of the First Nine Trials, But More Recently Win A String of Engle Trials

Update on November 1 post

Big tobacco's winning streak  came to an abrupt end, as predicted below.  As described in this Law.com article by David Bario, the end arrived with a plaintiff's verdict for  $ 80 million, which includes a punitive damages component at less than the  much-argued 10:1 ratio.   According to the article:

"Before the recent defense hegemony, plaintiffs lawyers at Searcy Denney Scarola Barnhart & Shipley had taken three Engle progeny cases to trial and won them all, including the last plaintiffs verdict before Big Tobacco began winning. Earlier this month, David Sales and James Gustafson went to trial with the firm's fourth Engle case. And on Monday, state court jurors in Bronson, Fla., delivered their client a verdict that breaks the defense winning streak in a big way.

The jury hit R.J. Reynolds with $72 million in punitive damages and $8 million in compensatory damages, finding that the tobacco company was 90 percent responsible for the death of James Horner, who died of lung cancer after smoking for 60 years. Here's the amended complaint Searcy Denney filed on behalf of Horner's daughter, Diane Webb; and here are the verdict forms the jury returned on compensatory and punitive damages.
 

November 1 Post ___________________________________________________________________________

In mass tort litigation involving repeated trials of similar issues, the outcomes can go back and forth as the parties shift strategies and tactics. Thus, Law.com reports that the cigarette companies recently have won six straight Engle trials in Florida. Plaintiff's counsel say they will keep trying cases, and estimate that the defendants are spending   $ 5 million per trial.  The defense string no doubt is encouraging for the defendants. 

But, the defense win streak follows an even larger number of wins for plaintiffs at the start of the series of trials, as described here. Defendants also lost their 11th Circuit effort to avoid the series of trials. So, now it's up to plaintiffs to look afresh at their tactics and see if the trial approach needs freshening or improvement.

Perhaps the David Bernick factor is now at work in the Engle trials. In any event, the Engle trials are just one part of part of global tobacco litigation, as described here and here. And then there are media efforts too.

Molecular Animation - Imagine these Videos in a Courtroom to Explain Disease Causation

The NYT's Erik Olsen compiled this wonderful on line article explaining and compiling examples of work from  the burgeoning world of molecular animation. It's how ideas and reams of data come to life and become manageable. The article includes multiple links to great animations, and identifies leaders in the field. The videos are great; make sure to check out The Inner Life of the Cell, which will take you to, of all places, You Tube.  While  there, look at some of the other similar videos that pop up.

Animations for accidents are now courtroom staples. Imagine tomorrow when a lawyer can use a video to demonstrate how a toxin destroys cells or alters genes. Remote concepts will become far simpler when they look like Pac Men. Defendants will have to counter. 

Tomorrow's trials will be very cool.

 

 

 

 

Tags:

Social Media Discovery - Many Forums and Rulings - Some Examples and a Law Review


Discovery of social media information is an interesting phenomenon, and very much in the news.   It seems to some that it's about the same thing as asking to see a person's scrapbook or photo album. Others say the on-line nature of the compilations makes this all much different.

Some recent case law is covered here by AmLaw's Alison Frankel. The topic also is receiving scholarly attention in an area where personal actions and statements are especially likely to be relevant – workers’ compensation claiming. Law professor Gregory M. Duhl and practicing lawyer Jaclyn Millner recently posted a draft of an article (to be published in the Pace Law Review) on the use of social networking evidence in insurance and workers' compensation litigation. The draft is available here on SSRN.  The article, Social Networking and Workers’ Compensation Law at the Crossroads, provides a broad and useful summary of the issues,  including some case law from outside the context of workers’ compensation. .

 

Social media issues of course are not confined to the US. Here’s an article addressing EU legislation on social media and privacy. It appears Europe is once again ahead of us when it comes to privacy.  

Social media discovery also may apply to corporations. Communications consultants routinely urge businesses to use and manage social media when involved in major litigation, or maintaining corporate image. One can expect plaintiff’s lawyers to start asking far more questions about what corporations are doing behind the front pages of social media.  

 

 

 

Litigation Funding - Series of Articles Started by the NYT and The Center for Public Integrity

Here is the first article in a promised series on litigation funding. A note at the end of the article states:

 "This project was initiated by the Center for Public Integrity, a nonprofit investigative news organization in Washington. It is based on reporting by Ben Hallman of the center and Binyamin Appelbaum of The Times, and was written by Mr. Appelbaum."

Here is an iteration of the article at  The Center for Public Integrity.

It will be interesting to see if the articles go into depth, and actually portray the realities of litigation. An encouraging sign is that the authors apparently interviewed Steven Yeazell, a real expert on the subject. Click here for a prior post which links to Prof. Yeazell's seminal paper on civil litigation funding. The same post also links to information on RAND's first seminar on litigation funding.  This later post links to information on RAND's second seminar on litigation funding.

The NYT article is followed by myriad uninformed "comments" by readers, with most attacking the US legal system and plaintiff's lawyers. One hopes they keep reading and learn. By reading and thinking, they might even figure out that widespread litigation funding actually decreases the market power of plaintiff's lawyers who historically have been the sole source for funding claims.

 

New Insights into The Global Tobacco Wars - Big Tobacco and Farmers Seek to Continue Sellings Carcinogens

Last week brought new insights into the global tobacco wars.  The insights are contained in information from four sources:

 

1)      the US Food and Drug Administration’s proposed new visual warnings for cigarette packages (click here to go to zipped package of the pictures)

2)      Duff Wilson’s Sunday front page NYT article detailing tobacco regulation litigation around the globe;  

3)       this Foley Hoag media piece regarding Uruguay retaining the law firm to defend it in a lawsuit filed by tobacco industry members; and

4)      this international treaty aimed at reducing the devastating human and financial tolls inflicted by sales of the packaged carcinogens commonly referred to as cigarettes.   

 

According to Mr. Duff’s article, “Uruguay’s groundbreaking law mandates that health warnings cover 80 percent of cigarette packages. It also limits each brand, like Marlboro, to one package design, so that alternate designs don’t mislead smokers into believing the products inside are less harmful.”  According to Foley Hoag, the litigation against Uruguay  “was initiated by FTR Holdings SA, a Swiss conglomerate that owns fellow plaintiffs Philip Morris as well as Abal Hermanos SA, the second-largest Uruguayan tobacco company.”

 

The big picture? Big tobacco, aided by tobacco farmers, has created a vast network to execute its strategy. The strategy?  Four steps.  First, sell packaged carcinogens to the addicted, uninformed and ignorant of the world.  Second, maintain the ability to sell by seducing governments with tax revenues or bludgeoning governments with litigation when meaningful regulations are imposed. Third, hire really smart litigation lawyers and settle litigation with agreements which perpetuate the opportunity to sell cigarettes. Fourth, create a vast web of corporate entities structured and operated to limit the assets reachable by disease victims, with litigators keeping the companies free of massive losses; losing slowly and in small amounts is acceptable because the companies remain wildly profitable.

 

Fighting back are some national governments, but many are woefully too small to effectively argue with big tobacco. 1As detailed by Mr. Duff, 171 countries meet this week in Uruguay to try to counter big tobacco. As detailed in an NYT article linked below, “the conference beginning on Monday in Punta del Este, Uruguay, will try to add specific terms to a public health treaty known as the Framework Convention on Tobacco Control, which since 2003 has been ratified by 171 nations. It would eventually oblige its parties to impose tighter controls on tobacco ingredients, packaging and marketing, expand cessation programs and smoke-free spaces and raise taxes — proven tactics against smoking.” 

 

The stakes are enormous in both lives and dollars. Globally, millions die every year from tobacco. WHO foresees 8 million annual tobacco cancer deaths by 2030.  And, as described in this prior post, The American Cancer Society estimates that tobacco-caused cancer deaths impose annual direct and indirect global economic costs of between $1.5 and 2 trillion. Remember, that's an annual number. No doubt it’s also too low because most cancer victims are left to die with no real fight to save them because their countries lack the necessary medical infrastructure.

 

What is the US doing? Not enough. In the US, we face daily headlines regarding medical care costs bankrupting companies and governments. Accordingly, one would think the United States would do all it can to stamp out sales of the leading and obvious cause of rampant, expensive diseases.  But that’s not been the case. President Bush focused his eight years on escalating multiple wars, but never found the time or courage to escalate the war against cancer deaths and big tobacco.  “President George W. Bush signed the treaty in 2004 but did not send it to the Senate, where a two-thirds vote is needed for ratification. President Obama hopes to submit it to the Senate next year, a White House spokesman said on Thursday.”    (The betting window is open as to the votes of tobacco state senators, and some but not all of their Blue Dog brethren.) 

 

Additional specifics follow, beginning with big picture information provided by Mr. Duff’s article, and concluding with specifics on big tobacco’s – shameful - litigation against Uruguay.  

 

NYT Excerpts

__________________________________________________________________________

“They’re using litigation to threaten low- and middle-income countries,” says Dr. Douglas Bettcher, head of the W.H.O.’s Tobacco Free Initiative. Uruguay’s gross domestic profit is half the size of the company’s $66 billion in annual sales.”

 

 

But Philip Morris International, the separate company spun out of Altria in 2008 to expand the company’s presence in foreign markets, has been especially aggressive in fighting new restrictions overseas.

 

 

It has not only sued Uruguay, but also Brazil, arguing that images the government wants to put on cigarette packages do not accurately depict the health effects of smoking and “vilify” tobacco companies. The pictures depict more grotesque health effects than the smaller labels recommended in the United States, including one showing a fetus with the warning that smoking can cause spontaneous abortion.

 

 

In Ireland and Norway, Philip Morris subsidiaries are suing over prohibitions on store displays.

 

In Australia, where the government announced a plan that would require cigarettes to be in plain brown or white packaging to make them less attractive to buyers, a Philip Morris official directed an opposition media campaign during the federal elections last summer, according to documents obtained by an Australian television program, and later obtained by The New York Times.”

 

 

Foley Hoag Excerpts

____________________________________________________________________

 

In a first-of-its-kind case focusing on areas of conflict between a nation’s tobacco control regulations and the treaty rights of a multinational corporation, the government of Uruguay has retained Foley Hoag LLP to represent it in an arbitration case brought by Philip Morris, at the International Centre for Settlement of Investment Disputes (ICSID).

 

 

The Foley Hoag team is led by international law specialists and Washington-based partners Paul Reichler and Ronald Goodman.

 

 

The current ICSID arbitration was initiated by FTR Holdings SA, a Swiss conglomerate that owns fellow plaintiffs Philip Morris as well as Abal Hermanos SA, the second-largest Uruguayan tobacco company. The cigarette manufacturers contend that Uruguay’s restrictions on sales and marketing of tobacco products, violate the bilateral investment treaty between Switzerland and Uruguay by harming the companies’ business operations and trademarked brands.

 

 

Uruguay enacted the measures as part of a broad effort to safeguard and enhance public health. In 2005 it became one of 170 countries to sign the World Health Organization’s Framework Convention on Tobacco Control, a global initiative to reduce or eliminate tobacco use. Soon after, the Uruguayan government introduced restrictions on cigarette marketing and packaging, including:

 

 

Limiting each brand of cigarette to a “single representation,” that is, forbidding multiple iterations of a brand such as “light,” “menthol,” etc.;

 

Requiring pictograms on tobacco packages to graphically illustrate the possible adverse health effects of sustained tobacco use;

 

Mandating that 80 percent of the surface area of cigarette packages be covered with health warnings to consumers.

 

 

Cigarettes sold in Uruguay include such well known Philip Morris brands as Marlboro and L&M, as well as locally made Casino and Premier brands. As a result of the regulations Philip Morris has ceased marketing Marlboro varieties called “Gold,” “Green (Fresh Mint),” and “Blue.” The claim alleges that the government’s actions violate both the 1988 Switzerland-Uruguay bilateral investment treaty and international law, by imposing unreasonable restrictions and subjecting FTR and its subsidiaries to unfair treatment.

 

 

Mr. Reichler believes the plaintiffs have targeted Uruguay as a test case. “Our view is that Philip Morris is hoping to use this case to deter not only Uruguay but other signatories to the WHO’s Framework Convention from taking effective measures to safeguard the public health against the known hazards of tobacco consumption,” he said.

 

“Sovereign states are normally given wide discretion in enacting legislation or promulgating regulations to protect and promote public health,” Mr. Reichler noted. “Indeed, that is one of the fundamental aspects of sovereignty. This is not a case of economic regulation, but of government action strictly in the name of public health.”

 

 

Mr. Goodman said, “Uruguay’s regulations are aimed at tobacco products which, it is scientifically proven, kill people or cause grave illnesses to those who smoke and to those around them. Because of the widespread illness, disease and mortality created by smoking, tobacco products impose tremendous burdens on a country’s public health system.   In many countries the state pays for or subsidizes the care and treatment of sick people. The financial burdens on states caused by smoking are enormous.”

 

 

“Philip Morris and its associated companies are challenging the right and discretion of Uruguay to make its own determination on how to protect public health – which in our view is a sovereign right that no private company can overrule,” Mr. Goodman added.

 

 

The Campaign for Tobacco-Free Kids, a U.S.-based research and advocacy organization funded by the Bloomberg Foundation, has agreed to help finance Uruguay’s defense.

 

 

The arbitral tribunal will be comprised of one arbitrator selected by each side and a third whom the parties agree on.

 

 

Philip Morris is represented by the Swiss firm Lalive

 

 

 

 

 

 

Tags:

Delaware the Tax Haven

Delaware certainly does what it can to bring people and entities  to the state to generate money for Delaware. This prior post noted the "race to the bottom"  initiated by Delaware judges seeking to make Delaware attractive as a forum for bankruptcy cases.  Now, from the Conglomerate, here's a brief summary of how Delaware deprives other states of tax revenue. The gist is that Delaware helps companies move income around by letting them create entities that own trademarks and are paid fees to help move income out of states with higher tax rates. According to the article, 22 states are now fighting back.  It surely seems difficult to respect financial engineering of this sort.

Evolution of the Mortgage Litigation Industry

The mortgage litigation industry is evolving in the US.  This article from the NYT describes a litigation industry response to banks mishandling mortgage documents and creating paper nightmares through the various ways they securitized mortgages and/or transferred rights to service mortgages. The response? Lawyers defending mortgage foreclosure cases for contingent fees, instead of hourly fees.

No doubt there will be complaints from Wall Street based lawyer bashers who dislike contingent fees. But the actions of the lawyers are examples of free market capitalism and entrepreneurial behavior, which are usally trumpeted as virtues by the  same critics.  Apparently lawyers are not allowed to be entrepreneurial. When the lawyer critics emerge, one way to avoid taking them too seriously is to spend a few minutes reading blog posts by the Epircurean Dealmaker, a Wall Street denizen who candidly rips his own kind in wonderful posts. Here's a classic example of the writing.

Meanwhile, in other developments, this NLJ article by Sheri Qualters describes the growing number of class actions spawned by banks which implemented "robo-signers" as  an illegal and immoral fix for sloppy (or worse) internal procedures.  Some might say that's also a classic example of entrepreneurial behavior.  

Here is a summary article by Alison Frankel on strategies that bondholders may use.

 

Rio Tinto International Litigation, Mediation Order and Example of a Young Lawyer Who Apparently Created a Fascinating Career Focused on Corporate Social Responsibility

Here is the link to a brief but very helpful summary of a decade of international tort litigation against Rio Tinto. The article includes its own helpful links, and keys on and links to a recent 9th Circuit opinion ordering mediation of the claims before considering an appeal.

Note also the fascinating career path of the author, Sarah Altschuller of Foley Hoag. Set out below is the text from her page at the firm's website. It looks like a smart, determined person can create a very special career. Note also her article on corporate due diligence on human rights issues.

 

"Sarah Altschuller has been a member of Foley Hoag’s Corporate Social Responsibility (CSR) practice since 2003. In this role, Sarah advises a wide range of multinational companies regarding the development and implementation of CSR strategies, policies, and procedures. She provides counsel regarding corporate interactions with socially responsible investors, and advice on stakeholder engagement with local communities, host governments, and non-governmental organizations. She also conducts site-level human rights and labor rights impact assessments, as well as due diligence efforts.

Sarah’s in-depth practical experience includes post-law school studies at North South University in Dhaka, Bangladesh (2002–2003), where she conducted research on how changing international trade regulations impact the country’s garment sector. Before entering law school Sarah conducted social research on publicly-traded domestic and international companies at KLD Research & Analytics, a socially responsible investment firm, currently part of RiskMetrics Group."

___________________

Hat tip to 'Lexology," an American Corporate Counsel which presents articles of interest by topic. Lexology included Sarah's article on the 9th Circuit's decision.

Trade Specific Marketing to Potential Asbestos Claimants

Amazing the things that Google drags up everyday. One is this U.S. law firm website page targeted at carpenters as mesothelioma claimants. 

The web page would be more apt for a UK law firm web page because UK carpenters actually face high risks because so many amphibole fiber products were so widely used in the UK. 

Will US Courts Yield to National Laws Which Thwart Discovery on Terrorism Lawsuits ?

Another interesting chapter is unfolding in Motley Rice's civil suit against alleged sponsors of the 9/11 attacks.  The issue now headed for the 2d Circuit - on a mandamus petition - is whether the district judge rightly sanctioned defendants for refusing to produce documents based on national laws intended to protect records against disclosure.

Various parallels are easy to envision, including, for example, Swiss secrecy laws, and old Canadian laws that created discovery issues in tort litigation. It's also not too hard to envision nationally important or sovereign-owned businesses operating under self-serving national statutes intended to thwart discovery. Think, for example, about Chinese drywall manufacturers.

AmLaw has been covering the story for some time. Go here for the current article with links to the petition, other briefs, and prior articles.  

'Fair Game," the Movie - Revisiting the Iraq Invasion, Joe Wilson, Valerie Plame, Dick Cheney, Scooter Libby, and Karl Rove

Remember Valerie Plame, Joe Wilson, and all the lies that were told by senior Bush Administration officails to try to cover up the trumped up basis for invading Iraq ?  The story is retold in  Fair Game,  with a focus on the marriage of CIA agent Valerie Plame Wilson and her former ambassador husband, Joe Wilson. The movie is well done and powerful. 

One caveat. Seeing the movie reinflames contempt for Dick Cheney, Karl Rove, Scooter, Fox "News,"and President  Bush's commutation of Scooter's sentence. 

I saw the  movie yesterday after I took the Multistate Ethics Exam, and so  was especially well-steeped in the ethical rules that are supposed to stop lawyers from lying. Hopefully Scooter stays disbarred forever.  Wikipedia covers his various post-conviction ploys and disbarments.

Tags:

National Cancer Institute (NCI) Issues Bulletin on Medical Monitoring Via Low Dose CT Scans - Results Tie to Medical Monitoring Claims Against Big Tobacco

Results are arriving from new science, and the news ties to medical monitoring claims against the tobacco industry.  Specifically, the National Cancer Institute issued yesterday a "breaking news" release regarding data emerging from long term, double-blind studies on using low dose CT scans to try to find lung cancers earlier in people with major smoking histories. The data released so far indicates that the CT scans are useful. More data is promised for the fairly near future. Here is the relevant NCI web page.  This prior post covered a Massachusetts Supreme Court ruling embracing medical monitoring claims in this context. Set out below are key excerpts from the NCI web page:

  1. What was the primary initial result of the NLST?
    NLST researchers found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT relative to chest X-ray. This finding was highly significant from a statistical viewpoint.

  2. Were there any other important findings from this study?
    An additional finding, which was not the main endpoint of the trial’s design, showed that all-cause mortality (deaths due to any factor, including lung cancer) was 7 percent lower in those screened with low-dose helical CT relative to those screened with chest X-ray. This finding should not be interpreted to mean that the general population should now get regular CT. These results apply to a high-risk population. Additionally, the risks of regular CT screens could be considerable, especially for relatively healthy people.

  3. When will the full set of results from this study be released?
    After a more comprehensive analysis of the findings from the NLST, the investigators will prepare manuscripts for publication in peer-reviewed journals. The NCI will ensure that the analysis and manuscript preparation are performed as swiftly as possible and that the formal presentations are fully and rapidly made available to the public.

 

Product Defects, Economic Loss Doctrine, and National Class Actions - The Toyota Example

AmLaw's Alison Frankel has provided this great primer on product defect claims, the economic loss doctrine, and national class actions. The primer arises from the litigation against Toyota for "sudden acceleration claims."   The primer is embodied in her post providing links to the key briefs on the issues. Great reading for anyone looking for a broad education on significant important issues.

A comment. The economic loss doctrine once made sense when most harms arose from smash, bang accidents with visible physical injuries. Today, however, the rule makes far less sense because sentient human beings today  know that injuries arise in many ways, including cellular level (subclinical personal injuries), and that risks of injury can and do create financial losses and costs. The common law needs to evolve to recognize modern science, modern risks, and modern financial losses. Or, courts need to make it very plain that they will not provide any remedies, thus leaving the choices narrowed down to something on the order of: 1) increasing regulation, 2) companies doing a far better job in designing and testing to avoid failure risks, or 3) consumers taking  the hit for design and testing failures.

A caveat and/or disclaimer. I own one of the defective Lexus cars. It never crashed, but I'm confident  I experienced numerous short, occasional accelerations caused by the car acting on its own. I took the car in for the recall work.  The sudden accelerations have not reappeared since the recall work.